Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shamir Mehta

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
JAMA Network Open|August 11, 2020
Comparison of Heart Team vs Interventional Cardiologist Recommendations for the Treatment of Patients With Multivessel Coronary Artery DiseaseMichael B Tsang, J D Schwalm, Sumeet Gandhi, et al.
JAMA Cardiology|March 20, 2024
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-AnalysisMarco Valgimigli, Felice Gragnano, Mattia Branca, et al.
European Heart Journal|August 23, 2021
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKDGiulio G Stefanini, Carlo Briguori, Davide Cao, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 24, 2022
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKDPayam Dehghani, Davide Cao, Usman Baber, et al.
Journal of the American College of Cardiology|August 17, 2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsGuiomar Mendieta, Shamir Mehta, Usman Baber, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 18, 2022
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG studyGennaro Sardella, Frans J Beerkens, George Dangas, et al.
JACC. Cardiovascular Interventions|October 25, 2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary InterventionDominick J Angiolillo, Davide Cao, Samantha Sartori, et al.
Lancet (London, England)|September 3, 2024
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trialsMarco Valgimigli, Sung-Jin Hong, Felice Gragnano, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 9, 2021
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT studyGeorge Dangas, Usman Baber, Samin Sharma, et al.
European Heart Journal|October 21, 2020
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACSUsman Baber, George Dangas, Dominick Joseph Angiolillo, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
JAMA Network Open|August 11, 2020
Comparison of Heart Team vs Interventional Cardiologist Recommendations for the Treatment of Patients With Multivessel Coronary Artery DiseaseMichael B Tsang, J D Schwalm, Sumeet Gandhi, et al.
JAMA Cardiology|March 20, 2024
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-AnalysisMarco Valgimigli, Felice Gragnano, Mattia Branca, et al.
European Heart Journal|August 23, 2021
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKDGiulio G Stefanini, Carlo Briguori, Davide Cao, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 24, 2022
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKDPayam Dehghani, Davide Cao, Usman Baber, et al.
Journal of the American College of Cardiology|August 17, 2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsGuiomar Mendieta, Shamir Mehta, Usman Baber, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 18, 2022
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG studyGennaro Sardella, Frans J Beerkens, George Dangas, et al.
JACC. Cardiovascular Interventions|October 25, 2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary InterventionDominick J Angiolillo, Davide Cao, Samantha Sartori, et al.
Lancet (London, England)|September 3, 2024
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trialsMarco Valgimigli, Sung-Jin Hong, Felice Gragnano, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 9, 2021
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT studyGeorge Dangas, Usman Baber, Samin Sharma, et al.
European Heart Journal|October 21, 2020
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACSUsman Baber, George Dangas, Dominick Joseph Angiolillo, et al.
Pageof 7